{
    "clinical_study": {
        "@rank": "26579", 
        "arm_group": [
            {
                "arm_group_label": "Cohort 1 - AMA0076 Dose A (or vehicle)", 
                "arm_group_type": "Experimental", 
                "description": "Consecutive, eligible subjects who meet the inclusion/exclusion criteria in each cohort will be randomized to active or placebo (vehicle) in a 4:1 allocation ratio (12 active : 3 placebo)."
            }, 
            {
                "arm_group_label": "Cohort 2: AMA0076 Dose B (or vehicle)", 
                "arm_group_type": "Experimental", 
                "description": "Consecutive, eligible subjects who meet the inclusion/exclusion criteria in each cohort will be randomized to active or placebo (vehicle) in a 4:1 allocation ratio (12 active : 3 placebo)."
            }, 
            {
                "arm_group_label": "Cohort 3: AMA0076 Dose C (or vehicle)", 
                "arm_group_type": "Experimental", 
                "description": "Consecutive, eligible subjects who meet the inclusion/exclusion criteria in each cohort will be randomized to active or placebo (vehicle) in a 4:1 allocation ratio (20 active : 5 placebo)."
            }, 
            {
                "arm_group_label": "Cohort 4: AMA0076 Dose D (or vehicle)", 
                "arm_group_type": "Experimental", 
                "description": "Consecutive, eligible subjects who meet the inclusion/exclusion criteria in each cohort will be randomized to active or placebo (vehicle) in a 4:1 allocation ratio (20 active : 5 placebo)."
            }
        ], 
        "brief_summary": {
            "textblock": "The objective of this dose-escalation study is to evaluate the safety, tolerability and\n      efficacy of AMA0076 in reduction of intraocular pressure in subjects with ocular\n      hypertension or primary open-angle glaucoma."
        }, 
        "brief_title": "Multiple Dose-escalation Study of AMA0076 in Patients With Ocular Hypertension or Primary Open-angle Glaucoma", 
        "completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Glaucoma", 
            "Ocular Hypertension", 
            "Eye Disease"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Eye Diseases", 
                "Glaucoma", 
                "Glaucoma, Open-Angle", 
                "Hypertension", 
                "Ocular Hypertension"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria include:\n\n          1. Adults 30-85 years of age\n\n          2. Diagnosis of either ocular hypertension or primary open-angle glaucoma in both eyes\n\n          3. Not receiving medication for IOP, or able to stop such medication for a washout\n             period and the duration of the study without significant risk of adverse consequences\n             related to glaucomatous disease\n\n          4. Elevated IOP (\u2265 24 and \u2264 34 mm Hg at 8 AM and \u2265 21 and \u2264 34 mm Hg at 10 AM on\n             Screening Two visit and Baseline visit in one or both eyes off treatment\n\n        Exclusion Criteria include:\n\n          1. Uncontrolled intraocular hypertension defined as >34 mm Hg at either of the\n             screening/baseline visits (after a washout phase in those subjects who were currently\n             receiving ocular hypotensive therapy).\n\n          2. Receiving more than one medication for IOP at time of screening.\n\n          3. Central corneal thickness of less than 500 \u00b5m or greater than 620 \u00b5m.\n\n          4. BCVA worse than 20/200 in either eye\n\n          5. Significant visual field loss (ie, mean deviation > 10 db or field loss within 10\n             degrees of fixation), a new field defect, or progression of an existing field defect\n             in either eye during the year preceding the study.\n\n          6. Acute angle-closure glaucoma or appositional or very narrow anterior chamber angle in\n             either eye."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "30 Years"
        }, 
        "enrollment": {
            "#text": "82", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 21, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01693315", 
            "org_study_id": "AMA0076-201"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Cohort 1 - AMA0076 Dose A (or vehicle)", 
                    "Cohort 2: AMA0076 Dose B (or vehicle)", 
                    "Cohort 3: AMA0076 Dose C (or vehicle)", 
                    "Cohort 4: AMA0076 Dose D (or vehicle)"
                ], 
                "intervention_name": "AMA0076", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Cohort 1 - AMA0076 Dose A (or vehicle)", 
                    "Cohort 2: AMA0076 Dose B (or vehicle)", 
                    "Cohort 3: AMA0076 Dose C (or vehicle)", 
                    "Cohort 4: AMA0076 Dose D (or vehicle)"
                ], 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "July 16, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Artesia", 
                        "country": "United States", 
                        "state": "California"
                    }, 
                    "name": "Artesia Clinical Site - Site 02"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Inglewood", 
                        "country": "United States", 
                        "state": "California"
                    }, 
                    "name": "Inglewood Clinical Site - Site 03"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Petaluma", 
                        "country": "United States", 
                        "state": "California"
                    }, 
                    "name": "Petaluma Clinical Site - Site 05"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New Haven", 
                        "country": "United States", 
                        "state": "Connecticut"
                    }, 
                    "name": "New Haven Clinical Site - Site 01"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Atlanta", 
                        "country": "United States", 
                        "state": "Georgia"
                    }, 
                    "name": "Atlanta Clinical Site - Site 04"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "High Point", 
                        "country": "United States", 
                        "state": "North Carolina"
                    }, 
                    "name": "High Point Clinical Site - Site 06"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Phase 2a, Randomized, Double-masked, Placebo-controlled, Dose-escalation Study of AMA0076 in Topical Ocular Formulation for Safety, Tolerability and Efficacy in Reduction of Intraocular Pressure in Subjects With Ocular Hypertension or Primary Open-angle Glaucoma", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "intraocular pressure change from baseline.", 
            "safety_issue": "No", 
            "time_frame": "4 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01693315"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Adverse events as a measure of safety/tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "4 weeks"
            }, 
            {
                "measure": "IOP assessments at weekly visits", 
                "safety_issue": "No", 
                "time_frame": "Weeks 1, 2, 3, 4"
            }
        ], 
        "source": "Amakem, NV", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Amakem, NV", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}